TG Therapeutics Inc
TGTX
NASDAQ
Biotechnology
$48.74
USD
+0.80 (+1.67%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $7.34B
Volume 1.1M
Revenue
$799.54M
TTM
+76.1%
YoY
Gross Margin
82%
TTM
-5.3%
YoY
Net Income
$441.49M
TTM
+630.2%
YoY
Operating Cash Flow
$17.88M
TTM
+130.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 141.1 | 161.7 | 192.6 | 204.9 | 240.3 |
YoY Growth | +92.1% | +92.8% | +78.0% | +69.6% | +70.3% |
Cost of Revenue | 18.9 | 28.1 | 38.1 | 33.5 | 41.2 |
Gross Profit | 122.2 | 133.6 | 154.4 | 171.4 | 199.1 |
Selling, General & Administrative | 59.9 | 12.4 | 28.6 | 20.0 | 90.2 |
Other Operating Expenses | 0.0 | 51.0 | 50.7 | 73.1 | 0.0 |
Total Operating Expenses | 87.4 | 104.3 | 103.9 | 136.6 | 177.5 |
Operating Income | 34.8 | 29.4 | 50.5 | 34.8 | 21.7 |
EBITDA | 34.9 | 29.5 | 50.4 | 34.8 | 21.7 |
Other Income / Expense | 2.8 | 3.3 | 1.1 | -6.8 | 5.1 |
Total Other Income / Expense | -3.9 | -3.5 | -5.4 | -14.4 | -11.4 |
Income Before Income Taxes | 30.9 | 25.9 | 45.1 | 20.4 | 10.2 |
Income Taxes | 2.7 | -365.0 | 22.1 | 0.6 | 2.5 |
Net Income | 28.2 | 390.9 | 23.0 | 19.8 | 7.8 |
Consolidated Net Income / Loss | 28.2 | 390.9 | 23.0 | 19.8 | 7.8 |
Net Income Attributable to Common Shareholders | 28.2 | 390.9 | 23.0 | 19.8 | 7.8 |
Basic EPS | $0.19 | $2.69 | $0.17 | $0.14 | $0.05 |
Diluted EPS | $0.17 | $2.43 | $0.14 | $0.12 | $0.05 |
Basic Shares Outstanding | 146.7M | 145.4M | 138.4M | 144.4M | 141.8M |
Diluted Shares Outstanding | 162.6M | 161.0M | 159.3M | 160.1M | 157.3M |